A platform that prints human tissue to help heal injury and disease

FOUNDERS

Tamer Mohammed

Sam Wadsworth

Simon Beyer

INDUSTRY

Biotechnology (Healthcare)

MILESTONE

Radical Investment: 2020

Aspect Biosystems occupies a unique place in the biotech market, having developed a platform for in-house innovation and licensed research partnerships with academia and industry. The promise of this technology – and its platform model – could reshape the business of tissue therapeutics.

Current tissues under development in Aspect’s bio engineering pipeline include personalized liver tissue as well as a pancreatic tissue for type 1 diabetes. Aspect’s proprietary bioprinting platform is behind over 20 collaboration projects with leading pharma, biotech and research centres around the world. In 2019 Aspect announced deals with GSK, Merck and JSR.

Founders

Tamer Mohamed
Sam Wadsworth
Simon Beyer

Founders

Kevin Terrell
Sumant Kawale
Yinhan Liu

Founder

Kaixiang Lin

Founders

Himanshu Gupta
Max Evans

Founders

Aidan Gomez
Nick Frosst
Ivan Zhang

Founders

Pieter Abbeel
Peter Chen
Rocky Duan
Tianhao Zhang

Founders

Alexandre Robicquet
Emile Contal
Sebastian Thrun

Founders

Evan Feinberg
Ben Sklaroff

Founder

George Sivulka

Founder

Kay Giesecke

Founder

Ann Garnier

Founders

Jonny Dyer
Dan McCleese
Pascal Stang
Paul Day
Reuben Rohrschneider

Founders

Awais Ahmed
Kshitij Khandelwel

Founders

Ramtin Attar
Reza Nasseri

Founders

Rishi Nayyar
Harsh Nayyar

Founder

Benjamin Schmidt

Founder

Corey Gross

Founders

Tomi Poutanen
Dr. Muhammad Mamdani
Mara Lederman

Founder

Ben Nashman

Founders

Jae Lee
Aiden Lee
SJ Kim
Soyoung Lee
David Chung

Founder

Charles Onu

Founders

Charles Fisher
Aaron Smith
Jonathan Walsh

Founders

Martin Snelgrove
Darrick Wiebe

Founder

Raquel Urtasun

Founder

Christian Weedbrook

Founders

Richard Socher
Bryan McCann

© 2022 Radical Ventures Investments Inc.